C7A
Non-Billable (Header)Malignant neuroendocrine tumors
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
What This Code Means
C7A is the ICD-10-CM diagnosis code for malignant neuroendocrine tumors. C7A sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neuroendocrine tumors (c7a).
Header codes like C7A cannot be reported on claims directly — they organize child codes that share clinical context but the actual diagnosis must be coded to the highest level of specificity supported by the documentation. Coders should look at C7A's child codes and select the one that matches the patient's documented presentation, since payers reject header codes submitted as the primary diagnosis. For risk adjustment workflows, header codes never contribute to a Medicare Advantage member's RAF score on their own; only billable child codes that happen to map to a payment HCC affect risk-adjusted plan payments.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C7A sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Excludes 2 — Not included here, may code separately
- malignant pancreatic islet cell tumors (C25.4)
- Merkel cell carcinoma (C4A.-)
Use Additional Code
- code to identify any associated endocrine syndrome, such as:
- carcinoid syndrome (E34.00)
Code Also
- any associated multiple endocrine neoplasia [MEN] syndromes (E31.2-)